Cantargia announced the strengthening of its management team through the appointment of Dr. Dominique Tersago as Chief Medical Officer (CMO) from 1 August 2022. Dr. Tersago brings broad experience at leading pharma and biotech companies and will advance Cantargia's medical activities and provide strategic guidance as the company prepares for late-stage clinical development of its lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), in pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC). Dr. Tersago has over 25 years of experience in clinical development and regulatory affairs, with a focus on immuno-oncology, virology, immunology and hematology.

She joins Cantargia from antibody start-up ExeVir Bio and brings significant industry experience, having held senior positions at high-profile life science firms including Bristol-Myers Squibb and Ablynx. At Ablynx, where she was CMO between 2013 and 2016 before it was acquired by Sanofi in 2018, Dr. Tersago had a key role in the phase III study design of caplacizumab for thrombotic thrombocytopenic purpura, later approved by both the EMA and FDA. Dr. Tersago has a medical degree from University of Antwerp, Belgium.

Dr. Roger Belusa, who had been acting as interim CMO, will remain at Cantargia and take up a role in the ongoing clinical trials. Another change to the management team is that VP CMC Peter Juul Madsen has decided to enter a new position outside Cantargia, and his role will be temporarily filled by Liselotte Larsson, COO.